READ NOW: Scientists expand research into Alzheimer’s disease to diversify treatments
One lesson: Timing might matter. Most of the failed anti-amyloid drugs were tested in people who already had at least mild symptoms. Some studies seeking to prevent memory loss in the first place still are underway. Several anti-tau drugs also are being tested.
Another lesson: Most people have a mix of dementias, which means they’ll need a variety of treatments.
“Now we have an opportunity — a real opportunity — to expand and try all these avenues,” said Alzheimer’s Association chief science officer Maria Carrillo.
The Alzheimer's Association leads the way to end Alzheimer's and all other dementia — by accelerating global research, driving risk reduction and early detection, and maximizing quality care and support. Our vision is a world without Alzheimer's and all other dementia.™ For more information, visit www.alz.org or call the 24/7 Helpline at 800.272.3900.